Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Human Papillomavirus Protein E6 (E6) Overview | 7 | 1 |
| Therapeutics Development | 8 | 3 |
| Human Papillomavirus Protein E6 (E6) Products under Development by Stage of Development | 8 | 1 |
| Human Papillomavirus Protein E6 (E6) Products under Development by Therapy Area | 9 | 1 |
| Human Papillomavirus Protein E6 (E6) Products under Development by Indication | 10 | 1 |
| Human Papillomavirus Protein E6 (E6) Pipeline Products Glance | 11 | 2 |
| Late Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Human Papillomavirus Protein E6 (E6) Products under Development by Companies | 13 | 2 |
| Human Papillomavirus Protein E6 (E6) Products under Development by Universities/Institutes | 15 | 2 |
| Human Papillomavirus Protein E6 (E6) Therapeutics Assessment | 17 | 5 |
| Assessment by Monotherapy/Combination Products | 17 | 1 |
| Assessment by Route of Administration | 18 | 2 |
| Assessment by Molecule Type | 20 | 2 |
| Human Papillomavirus Protein E6 (E6) Companies Involved in Therapeutics Development | 22 | 9 |
| BioNTech AG | 22 | 1 |
| Cancer Research Technology Limited | 23 | 1 |
| Etubics Corporation | 24 | 1 |
| Genexine, Inc. | 25 | 1 |
| Inovio Pharmaceuticals, Inc. | 26 | 1 |
| MedImmune, LLC | 27 | 1 |
| Selecta Biosciences, Inc. | 28 | 1 |
| Tomegavax, Inc. | 29 | 1 |
| Transgene SA | 30 | 1 |
| Human Papillomavirus Protein E6 (E6) Drug Profiles | 31 | 20 |
| Antibodies to Target E6 for HPV Associated Cancer Drug Profile | 31 | 1 |
| ETBX-041 Drug Profile | 32 | 1 |
| GX-188E Drug Profile | 33 | 2 |
| human papillomavirus [serotypes 16] vaccine Drug Profile | 35 | 1 |
| human papillomavirus vaccine Drug Profile | 36 | 1 |
| INO-3106 Drug Profile | 37 | 1 |
| INO-3112 Drug Profile | 38 | 2 |
| PVX-01 Drug Profile | 40 | 1 |
| SEL-701 Drug Profile | 41 | 1 |
| Synthetic Peptide to Inhibit HPV E6 Protein for HPV Associated Cancer Drug Profile | 42 | 1 |
| TA-CIN Drug Profile | 43 | 1 |
| TG-4001 Drug Profile | 44 | 2 |
| Vaccine for Cervical Intraepithelial Neoplasia Drug Profile | 46 | 1 |
| VGX-3100 Drug Profile | 47 | 3 |
| Vvax-001 Drug Profile | 50 | 1 |
| Human Papillomavirus Protein E6 (E6) Dormant Projects | 51 | 1 |
| Human Papillomavirus Protein E6 (E6) Discontinued Products | 52 | 1 |
| Human Papillomavirus Protein E6 (E6) Featured News &Press Releases | 53 | 12 |
| Mar 30, 2016: Inovio Pharmaceuticals HPV Immunotherapy Selected as Best Therapeutic Vaccine by World Vaccine Congress | 53 | 1 |
| Mar 29, 2016: Inovio Updates INO-3112 HPV Immunotherapy Development Plan | 53 | 1 |
| Nov 05, 2015: Inovio s INO-3112 Shows Robust Immune Responses in Patients With Head &Neck Cancer | 54 | 1 |
| Sep 17, 2015: Inovio Pharmaceuticals Publishes Successful Phase 2b Trial Results of Its HPV Immunotherapy in The Lancet | 55 | 1 |
| Jul 23, 2015: Inovio Pharmaceuticals and European Organization for Research and Treatment of Cancer to Collaborate on Large Phase II Cervical Cancer Trial | 56 | 1 |
| Apr 09, 2015: Inovio Pharmaceuticals' HPV Immunotherapy Recognized as "Best Therapeutic Vaccine" by World Vaccine Congress | 57 | 1 |
| Apr 09, 2015: Inovio Pharmaceuticals HPV Immunotherapy Activates Robust In Vivo T Cell Responses in Head &Neck Cancer Patients | 58 | 1 |
| Dec 23, 2014: Selecta and Skolkovo Foundation Collaboration to Develop a Synthetic Vaccine Particle in the field of Immuno-oncology | 59 | 1 |
| Oct 30, 2014: Genexine s HPV Therapeutic Vaccine Achieved High Efficacy in Phase I Cervical Dysplasia Trial | 59 | 1 |
| Sep 22, 2014: Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers | 60 | 1 |
| Jul 23, 2014: Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial | 60 | 1 |
| Jun 11, 2014: Inovio Pharmaceuticals Clarifies Facts of its VGX-3100 Phase II Trial and Immunotherapy Technology | 61 | 1 |
| Jun 10, 2014: Inovio Pharmaceuticals Initiates Immune Therapy Trial for Head &Neck Cancer Caused by HPV | 62 | 1 |
| Jul 01, 2013: Etubics Awarded Grant To Develop HPV Immunotherapy Targeting Head &Neck Cancer | 63 | 1 |
| Nov 26, 2012: Inovio Pharma's Cytomegalovirus Synthetic Vaccine Generates Strong And Broad T-cell Responses In Preclinical Study | 64 | 1 |
| Appendix | 65 | 2 |
| Methodology | 65 | 1 |
| Coverage | 65 | 1 |
| Secondary Research | 65 | 1 |
| Primary Research | 65 | 1 |
| Expert Panel Validation | 65 | 1 |
| Contact Us | 65 | 1 |
| Disclaimer | 66 | 1 |